Nexalin Technology Inc. (NXL) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Nexalin Technology Inc. (NASDAQ: NXL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.51 (-5.94% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NXL ranks #747 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NXL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, NUWE (Nuwellis Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and VBIO (Valion Bio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M). Among the 5-stock peer group, NXL leads on earnings multiple (N/A) while NXL leads on capital efficiency (-35.0% ROIC).
Per NXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001527352), Nexalin Technology Inc. generated $301.6K in revenue (+78.8% YoY), -$8.2M in net income, and -$5.0M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.6 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While NXL currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.29) and Max Pain ($1.59) forces dealer call-delta covering toward $47.25.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Nexalin Technology Inc. (NXL) dropped -5.94% to $1.51, trading at 2% of its 52-week range ($1.51 – $45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journalStatistically significant improvement in
Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock moved
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +78.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NXL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NXL. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Nexalin Technology Inc. (NXL) ranks #747 by composite RQD confidence (32/100, grade E) and #998 by equity capitalization ($1.8M). Within this direct 5-issuer industry benchmark cohort, NXL leads on earnings valuation at N/A trailing P/E, while NXL leads on capital efficiency and profitability with -35.0% ROIC and 79.7% gross margin. VBIO currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with NXL at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NXL
ACTIVE
Nexalin Technology Inc. | E | 32/100 | — | 79.7% | -35.0% | -5.94% | $1.8M | Benchmark Subject |
| NUWE Nuwellis Inc. | E | 33/100 | — | 62.0% | -35.0% | -8.80% | $2.3M | /nuwe-vs-nxl → |
| VBIO Valion Bio Inc. | D- | 36/100 | — | — | -35.0% | -3.47% | $1.2M | /vbio-vs-nxl → |
| NDRA ENDRA Life Sciences Inc. | D- | 36/100 | — | — | -35.0% | +1.05% | $7.1M | /ndra-vs-nxl → |
| IRIX IRIDEX Corporation | E | 27/100 | — | 36.5% | -35.0% | +1.33% | $12.5M | /irix-vs-nxl → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nexalin Technology Inc. (NXL) reported GAAP revenue of $301.6K (+78.8% vs. FY2024 revenue of $168.7K , and +172.4% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$5.0M, and free cash flow of -$5.0M (-25.7% YoY). On the balance sheet, NXL closed FY2025 with $4.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $301.6K | -$8.2M | -$5.0M | -$5.0M | $4.6M | — |
| FY2024 (FY) | 2024-12-31 | $168.7K | -$7.6M | -$3.9M | -$3.9M | $4.2M | — |
| FY2023 (FY) | 2023-12-31 | $110.7K | -$4.6M | -$3.8M | -$3.8M | — | — |
As of 2026-11-03, Nexalin Technology Inc. (NASDAQ: NXL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.51 (-5.94% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NXL ranks #747 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NXL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, NUWE (Nuwellis Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and VBIO (Valion Bio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M). Among the 5-stock peer group, NXL leads on earnings multiple (N/A) while NXL leads on capital efficiency (-35.0% ROIC).
Per NXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001527352), Nexalin Technology Inc. generated $301.6K in revenue (+78.8% YoY), -$8.2M in net income, and -$5.0M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
NXL last traded at $1.51 (-5.94% on volume of 11,870 shares), positioning the stock -64.80% below its 50-day simple moving average ($4.29) and -85.90% below its 200-day simple moving average ($10.71). Across its 52-week range of $1.51 to $45.00, NXL sits at the 0.0% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.32 to $1.70).
Nexalin Technology Inc. (NXL) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.51 (-5.94% 1D, market capitalization $1.8M).
And profile, Nexalin Technology Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Revenue is small, reported as $0.3M for FY 2025. The profile does not describe its products, customers, or specific revenue model. Gross margin is reported at 79.7%, while operating margin is -60%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nexalin Technology Inc. (NXL) reported $301.6K in annual revenue (up from $168.7K in FY2024, +78.8% YoY) and -$8.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($110.7K revenue, -$4.6M net income) through FY2025, NXL scaled operating cash flow to -$5.0M and free cash flow to -$5.0M, backed by $4.6M in total assets against $0 in total debt.
Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), NXL carries a macro regime beta of 1.00 and gross margin of 79.7%.
Real-time company headlines, analyst actions, and sector developments for Nexalin Technology Inc. (NXL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Nexalin Technology Inc. (NXL) market action, institutional positioning, and fundamental catalysts.
Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journalStatistically significant improvement in
The street is overcomplicating Nexalin Technology Inc. (NXL). The company regained Nasdaq minimum bid price compliance and received a continued-listing grant from a Nasdaq Hearings Panel.. With an RQD score of 32/100 (E) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.73.
@DeepValue_CFA Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.60 and keeping dry powder in case we test $1.49.
Careful chasing NXL at $1.60. Operating losses of -$8.4M on $0.3M revenue in FY 2025, with ROIC at -35% and FCF yield at 0%, against cash of $0.7M.. Gross margin is 79.7%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.34 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: